GERON CORP (GERN) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US3741631036
GERON CORP financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -68.59 m USD |
| EBIT | -68.89 m USD |
| Net income | -83.50 m USD |
| Diluted EPS – continuing operations | -0.13 USD |
Full history since 1996, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About GERON CORP
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
More stocks
- PVA TePla (TPE.DE)
- TIPTREE INC. (TIPT)
- Ningbo David Medical Device Co Ltd (300314.SZ)
- CJ CGV (079160.KS)
- Fuchun Technology Co Ltd (300299.SZ)
- Pacific Assets Trust PLC (PAC.L)
- Guangzhou Hongli Opto Electron (300219.SZ)
- Shenzhen Minglida Precision Technology Co. Ltd. (301268.SZ)
- Shandong Meichen Science & Technology Co Ltd (300237.SZ)
- Cresud SACIF y A (CRESY)
- Xilong Chemical Co Ltd (002584.SZ)
- Aimer Co. Ltd. (603511.SS)
Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.